HQL vs. STEW, CET, QQQX, GAM, MFIC, MUC, SLRC, MQY, HQH, and MYI
Should you be buying Abrdn Life Sciences Investors stock or one of its competitors? The main competitors of Abrdn Life Sciences Investors include SRH Total Return Fund (STEW), Central Securities (CET), Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX), General American Investors (GAM), MidCap Financial Investment (MFIC), BlackRock MuniHoldings California Quality Fund (MUC), SLR Investment (SLRC), BlackRock MuniYield Quality Fund (MQY), Abrdn Healthcare Investors (HQH), and BlackRock MuniYield Quality Fund III (MYI). These companies are all part of the "investment offices, not elsewhere classified" industry.
SRH Total Return Fund (NYSE:STEW) and Abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.
15.6% of SRH Total Return Fund shares are held by institutional investors. Comparatively, 32.2% of Abrdn Life Sciences Investors shares are held by institutional investors. 0.1% of SRH Total Return Fund shares are held by insiders. Comparatively, 10.1% of Abrdn Life Sciences Investors shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Abrdn Life Sciences Investors had 4 more articles in the media than SRH Total Return Fund. MarketBeat recorded 4 mentions for Abrdn Life Sciences Investors and 0 mentions for SRH Total Return Fund. SRH Total Return Fund's average media sentiment score of 1.59 beat Abrdn Life Sciences Investors' score of 0.00 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the news media.
SRH Total Return Fund has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Abrdn Life Sciences Investors has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
SRH Total Return Fund pays an annual dividend of $0.52 per share and has a dividend yield of 3.6%. Abrdn Life Sciences Investors pays an annual dividend of $1.49 per share and has a dividend yield of 10.8%. SRH Total Return Fund has increased its dividend for 3 consecutive years.
Abrdn Life Sciences Investors received 95 more outperform votes than SRH Total Return Fund when rated by MarketBeat users.
Summary
Abrdn Life Sciences Investors beats SRH Total Return Fund on 6 of the 8 factors compared between the two stocks.
Get Abrdn Life Sciences Investors News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abrdn Life Sciences Investors Competitors List
Related Companies and Tools
